Gastric ulcer healing with tripotassium dicitrato bismuthate and subsequent relapse.

Abstract

Fifty patients with endoscopically proven gastric ulcers completed a one month double-blind randomised trial of tripotassium dicitrato bismuthate (TBD) (DeNol) compared with an identical placebo. Ulcer healing occurred in 18 (72%) of the 25 patients given TDB and in nine (36%) of the patients given placebo. The TDB group experienced significantly less pain than the placebo group. During a follow-up of 29 patients with healed ulcers for up to 44 months, relapse occurred in 13 (45%). It was highest in the first three months (27%) and had risen to 41% at two years.

• Authors: D R Sutton
• Journal: Gut (Gut) Vol. 23 Issue 7 Pg. 621-4 (Jul 1982) ISSN: 0017-5749 [Print] England
• PMID: 7044913 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Ulcer Agents
• Organometallic Compounds
• bismuth tripotassium dicitrate
• Bismuth

Topics

• Anti-Ulcer Agents (therapeutic use)
• Bismuth (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Organometallic Compounds
• Random Allocation
• Recurrence
• Stomach Ulcer (drug therapy)